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ABSTRACT 
 
 
 Micronization is one of the common processes for size reduction to increase 
surface area of poorly soluble Active Pharmaceutical Ingredient’s (API). This size 
reduction improves the dissolution rate and permeability thereby increasing the 
bioavailability for hydrophobic API’s. 
 
 Tablets and capsules are the most marketed and easy to manufacture solid dosage 
forms. During manufacturing of tablets, high compression forces are applied uniaxially 
on the powder bed to get a coherent consolidated compact with good tensile strength. So, 
diluents are required to mix with API’s and compress into tablets. When this mixture is 
compressed into tablets, there is a possibility of agglomeration of micronized API to API 
particles together within the tablet due to their high surface area and high surface free 
energy during compression.  Increasing the particle size and decreasing the surface is 
generally expected to decrease the dissolution rate of the API. 
 
 Micronized furosemide and griseofulvin were used as model API’s based on the 
biopharmaceutical classification system to study the effect of compression force on 
particle agglomeration during compression and also to study the processes and materials 
to prevent that agglomeration. The size of furosemide and griseofulvin particles was 
measured after disintegration of tablets compressed by varying compression forces and 
drug loading. Effect of size of diluents on agglomeration of API’s was also studied by 
varying the size of diluents like lactose mono hydrate and dicalcium phosphate dihydrate. 
The bonding mechanism for formation of agglomerates of these API’s during 
compression was studied by comparing the tensile strength of the compacts soaked and 
dried in solvents of various dielectric media. Prevention of micronized particle 
agglomeration during compression was studied by using particle agglomeration inhibitors 
like PEG 3350, Lutrol F68 micro, hydroxyl propyl starch polymer and by various 
treatment methods like physical mixing, hexane slurry method, roller compaction and 
spray drying. The particles were characterized for change in crystal structure, 
polymorphism and surface morphology by X-ray diffraction, thermal studies and 
microscopy studies.  
 
 Micronized furosemide and griseofulvin particle size was increased significantly 
and linearly by increasing the drug loading and compression force during compression. 
The size of the formed agglomerates was directly proportional to particle size of diluents. 
The dominating bonding mechanism responsible for agglomerate formation was found to 
be solid bridge formation between drug particles during compression. The API to API 
particle agglomeration during compression was successfully prevented by using particle 
agglomeration inhibitors (PAI’s).  Treatment with hexane and increase in the level of 
super disintegrant provided limited prevention of agglomeration during compression for 
furosemide particles. The spray drying with either mannitol or hydroxy propyl starch for 
micronized furosemide significantly reduced the agglomeration of API particles during 
compression. Roller compaction process with Lutrol F68 micro and PEG 3350 provided 
significant reduction in the agglomeration of drug particles for both the API’s during 
 vi 
compression. Compression force and treatment with PAI’s on polymorphism was 
observed in changing the crystal structure and polymorphism during compression and 
confirmed by thermal and X-ray crystallographic studies for both the API’s. Scanning 
Electron Microscopy studies revealed compression force and roller compaction process 
with PAI’s changed the surface morphology of both the API’s.  
 
 The results of the above studies indicated that compression of micronized 
hydrophobic poorly soluble drugs into tablets affects the dissolution rate due to 
agglomeration of API. The micronization process for improving the dissolution rate of 
poorly soluble drugs showed disadvantageous with respect to tablets compressed at high 
compression forces because of agglomeration of furosemide and griseofulvin particles 
during compression. Hence control of particle size and selection of size of diluents are 
necessary during formulation of tablets of hydrophobic poorly soluble drugs. Primary 
particle size increase of micronized hydrophobic drugs during compression can also be 
minimized by treatment with particle agglomeration inhibitors prior to compression. 
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CHAPTER 1.    INTRODUCTION 
 
 
Poor aqueous solubility and poor oral bioavailability of drugs are the two most 
discussed topics in the published pharmaceutical research. Most of the new chemical 
entities synthesized currently through traditional combinatorial chemistry or through 
analogous synthesis schemes are hydrophobic in nature and are difficult to dissolve in 
aqueous solutions. The desired pharmacological response for administered drug can be 
manifested only when it is available in sufficient concentration at receptors.1 At present 
40% of the new chemical entities in the developmental pipeline are poorly soluble, and 
even up to 60% of the compounds coming directly from synthesis are poorly soluble.2-5 
Some diseases need chronic drug treatment and other diseases need acute or short term 
drug therapy. Chronic drug therapy or extended drug treatment can be achieved by 
modifying drug release characteristics from dosage forms. For acute drug therapy, most 
of the patients prefer injections, solutions or immediate release solid dosage forms. The 
oral route is generally the preferred route of drug administration where possible, due to 
patient compliance, convenience and lower production costs. For any drug to be absorbed 
into systemic circulation after oral administration that drug should dissolve in the gastric 
fluids.6 For better therapeutic response the drug must be in molecular dispersion form that 
means a true solution at absorption site. According to Biopharmaceutical Classification 
System the drug dissolution and gastrointestinal permeability are the fundamental 
parameters controlling the bioavailability of drugs.7 Absorption of drugs through the 
intestine is purely depends on their physicochemical properties like molecular weight, 
pKa, logP, solubility, intrinsic dissolution rate, polymorphic nature of drug, particle size, 
pH environment of gastro intestinal tract and its content. Based on the aqueous solubility 
and intestinal permeability the biopharmaceutical classification system classified the 
drugs into four categories. For any drug substance classified as highly soluble in BCS 
class I and class III category its highest dose should be soluble in 250 ml or less aqueous 
medium at pH range of 1.0-7.5.8 Dissolution of a drug in the gastrointestinal fluids is 
often the rate limiting step for oral bioavailability. According to Noyes-Whitney in 
Equation 1-1.9 
 
                                                    
ܹ݀
݀ݐ =
ܦܣሺܥݏ − ܥሻ
ℎ                                           (Eq. 1-1) 
 
 Where dw/dt is the rate of dissolution of a drug, D is the diffusion coefficient of a 
drug, A is the surface area of a drug accessible to dissolution media, Cs is the 
concentration of a drug surrounding layer of a solid, C is the concentration a drug in the 
bulk dissolution media which is negligible compared to Cs10, h is the thickness of a 
diffusion layer. In the above Equation 1-1, the diffusion coefficient D is depends on the 
viscosity of gastrointestinal fluid and/or its contents and the thickness of a diffusion layer 
h depends on the hydrodynamics during gastrointestinal transit.11 These latter two 
parameters have less impact as a target to improve the dissolution rate of poorly soluble 
drugs. The other two terms in the Equation 1-1 can be used to improve bioavailability by 
increasing the surface area and by increasing the saturation solubility. Several literature 
sources discussed saturation solubility increasing with decrease in particle size.12-14 
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 Dissolution rate increase can be achieved by reducing the particle size of the drug 
and optimizing the wetting characteristics of compound surface to decrease the diffusion 
layer thickness and by increasing the apparent solubility of a drug.15 Christer. N et al., 
studied the milled griseofulvin and found that the increase in solubility was due to 
increase in surface free energy and reduction in heat of fusion and disordering of solid 
structure.16 Currently; there are numerous techniques available to increase the dissolution 
rate by particle size reduction to micro and nano size,17-20 by forming solid 
dispersions,21,22 by forming inclusion complexes with cyclodextrins23,24 and by forming 
salts.25 Increase in dissolution rate of poorly soluble drugs by micronization is a well-
known topic.26 For some drugs, like griseofulvin the degree of alimentary absorption and 
increase in blood concentration is directly proportional to particle size.27 Instability of 
solid dispersion systems28 and the size of the molecule and its conformational fit for 
inclusion complexation with cyclodextrin ring are some of the disadvantages.29 Among 
these techniques the size reduction to micron or nano size is one of the suitable 
techniques to get successful enhancement of dissolution rate for poorly soluble drugs.30 
Currently marketed and under development technologies for poorly water soluble drug 
substance are presented in Table 1-1.31 
 
 
1.1 Micronized Powder Properties 
 
 Knowledge about micronized or nano sized powder properties is very important 
in the pharmaceutical industry. The major and important properties of micronized 
powders are 1) individual particle shape and surface area, 2) particle size distribution and 
total surface area. As the dissolution rate of poorly soluble drugs increases with 
decreasing the particle size, the estimation of particle size is an important material 
characterization parameter in the drug development stage. Generally the particle size is 
expressed in microns (µm, micrometer) or nanometer (nm). But for dissolution generally 
must be related to surface area. The most critical part of particle size analysis is method 
development and validation. There are several methods in practice across the industry for 
estimation of particle size. Some practical issues to be considered in estimation particle 
size, in dry method the particles could be exposed to significant stress as this method uses 
heavy air streams. Whereas in wet analysis, the material should not be soluble in the 
dispersant and it should compatible with the wetting agent used in the media. The impact 
of shear due to sonication during measurement should be evaluated so that the particles 
should not be fractured. 
  
The micron (10-6) or nano (10-9) size particles are very small in size; their surface 
area will be large because of generation of new surfaces during micronization process. 
This increase in surface area is responsible for hastening the dissolution rate of poorly 
soluble drugs. Surface area of powders can be measured normally by Brünauer-Emmett-
Teller or B.E.T method and expressed as specific surface area.  
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Table 1-1. Marketed approaches to solubility enhancement of poorly water- soluble drug substances 
 
Particle size Method Process Technology Owner Marketed products 
Micron (nano particle) Down-sizing Milling Nanocrystal Elan Rapamune
®, 
Emend® 
 
Down-sizing Homogenation IDD SkyePharma Triglide™ 
Down-sizing Homogenation Nanopure PharmaSol Under development 
Down-sizing Homogenation Nanoedge Baxter Under development 
Down-sizing SCF SCF milling DuPont Under development 
Build-up SCF SFEE Ferro Corp Under development 
Build-up SCF SAS-EM™ Thar Tech Under development 
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1.2 Mixing of Micronized Powders 
 
 Mixing of micronized powders along with other excipients in drug development is 
a crucial and cumbersome process. Two types of mixing exist to get good blend 
homogeneity in solid dosage form development. They are 1) ordered mixing, 2) random 
mixing. The mixing process is represented in Figure 1-1. Ordered mixture is formed by 
mixing fine cohesive powders and coarse free flowing powders. Adsorption of fine 
particles on coarse particles determines the homogeneity of the blend. For any random 
mixture the particles in the blend need not to be in different size, but the content of the 
sample taken from the random mixture at any place in the mixture should be same.32,33 
Particle segregation and agglomeration are the two major problems that could arise 
during blending of different size powders. With some limitations the ordered mixing 
process reduces the segregation. This segregation and agglomeration can be minimized 
by modifying the particle size and the shape of the drug particles.34 Type and extent of 
particle adsorption can be shown to be dependent on the size and physicochemical 
properties of the particles. For some drugs like antibiotics adsorbs more on sorbitol 
instant pharma compared to crystalline sorbitol due to its high adsorption capacity and 
binding strength.35 For micronized cohesive hydrophobic drugs like griseofulvin the 
ordered mixing process by mixing with sodium chloride as diluent increased the contact 
surface area exposed to dissolution media.36 Hydrophobic diluents such as di calcium 
phosphate dihydrate gave limited increase in the dissolution rate of griseofulvin suggests 
that use of a soluble diluent is preferred. The higher degree of surface coverage by drug 
particles on carriers by ordered mixing increased the dissolution rate of griseofulvin 
blend as well as tablets. This effect was altered by increasing the drug loading and also 
due to formation of drug film on carrier particles which blocks instantaneous dissolution 
of the latter.37,38 
 
 
1.3 Compaction of Micronized Powders 
 
 Particle size importance during compaction of powders was studied over the 
years.39-41 Eighty per cent of the human use and marketed dosage forms are tablets.42 
Tablets are the most patient compliant, suitable for large scale production and cost 
effective unit dosage forms in the market. All tablets should possess adequate mechanical 
strength to with stand processing and transportation and deliver the drug in a 
predetermined pattern. 
 
The effect of compression force on particle size distribution will provide 
information about the particles morphology. During the tableting process, the massive 
compression force applied to the powder bed induces considerable deformation in the 
solid particles. The expected data from these compression studies should provide whether 
the particles undergoing any morphological changes during compression like formation 
of large crystals or aggregates by melting or formation of high energy fine solid particles 
by fragmentation. For most of the pharmaceutical blends these forces are large enough to 
exceed elastic limit of the solid that lead to breakage of particles by fracture. 
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Figure 1-1. Powder mixing patterns 
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1.3.1 Stages of compression 
 
When an external force is applied uniaxially on a powder bed in a die its volume 
reduces and its interparticulate porosity decreases. The term compressibility is defined as 
the ability of a powder material to reduce its volume under pressure, whereas the 
compactability is the ability of a material to form a solid compact with specific 
mechanical strength.43 Stages of powder compression are presented in Figure 1-2.44 
 
An external force applied on a powder bed initially forces the small particles in 
the powder blend to rearrange by sliding and fill the voids between the particles. Upon 
further increasing the force there will be a friction between particles that prevents further 
relative movement of the particles inside the die and powder forced to transform into a 
denser solid compact. At this stage the powder particles at contact points feel stress and 
start to deform. If the deformed powder particles regain their original shape upon removal 
of the force then it is called elastic deformation which is a reversible process. If this 
deformation is irreversible that is called as plastic deformation. For most of the plastically 
deformed materials fragmentation occurs further and they break into smaller particles 
upon increase in applied force. These small particles with new surface increase the 
compact strength by forming interparticulate bonding due their high surface area and 
surface energy. In summary one single particle undergo several of these processes during 
compression and with the other materials can form a coherent compact with the well-
defined shape of a tablet. As the compression force increases the specific surface area of 
the particles increases proportionately to some extent and then reduction in the specific 
surface area is observed due to agglomeration of fragmented particles. The sequences of 
events occur during tablet compaction process are: a) particle rearrangement, b) elastic 
deformation, c) plastic deformation, d) particle fragmentation, e) formation of 
interparticulate bonds.39,45,46 
 
 
1.3.2 Particle bonding and bonding mechanism 
 
 The two important factors for compactability of powders are the dominating bond 
mechanism and the surface distance over which these bonds are active.47 The volume 
reduction during compression is an endothermic process that normally requires more 
energy to form a compact with high surface area by interparticulate attraction forces. 
Particle bonding during compression is an exothermal process that releases energy.48 
Most of the pharmaceutical materials possess poor thermal conductivity and low specific 
heat. Increase in mechanical strength of a compact by particle/ particle interaction can be 
defined as consolidation. A number of mechanisms have been proposed for 
interparticulate bonding during compression a) solid bridges caused by melting and 
subsequent cooling, b) mechanical interlocking between irregularly shaped particles, c) 
attractive forces like coulomb forces between charged particles, d) covalent bonds, e) 
hydrogen bonds and f) van der Waals forces.49,50 For simplicity the dominating bonding 
mechanisms can be limited to three: 1) solid bridges, 2) distance attraction forces, 3) 
mechanical interlocking.51 Some specifications of bonding mechanisms in compacted dry 
powders are presented in Table 1-2.47 
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Figure 1-2. Stages of compression 
 
Modified with permission: Marshall K. 1986. Compression and consolidation of 
powdered solids. In Leon Lachman HAL, Joseph L. Kanig, editor The Theory and 
practice of Industrial Pharmacy, 3 ed., Philadelphia: Lea and Febiger. p 66-99. 
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Table 1-2. Some specifications of bonding mechanisms in compacted powders 
 
Type  
(bonding) 
Dissociation energy 
(kcal/mol) 
Separation distance 
at equilibrium  
(Å) 
Maximum 
attraction 
distance (Å) 
Solid bridges  <2  
Covalent 
homopolar 50-150 < 2 
< 10 Covalent heteropolar 100-200 <2 
Ionic 100-200 < 3 
Inter molecular forces 
Hydrogen bonding 2-7 3-4 
100-1000 van der Waals 1-10 3-4 
Electrostatic   
Mechanical 
interlocking 
Variable depends on the shape, bulkiness and flakiness of the 
particles 
 
Å: Angstroms 
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 During the compression process the particles in direct contact with the upper and 
lower punch surfaces undergo a pressure effect. Inside the powder bed the particles 
undergo stress due to particle-to-particle contact. The area at which particle-particle in 
contact is very small and pressure exerted at contact points can be extremely high. This 
can raise the temperature and melt the powder particles during compression. For surface 
fusion there should be formation of localized high temperature hotspots. If the 
temperature of these hotspots reaches the melting point of the substance being 
compressed, the surface fusion can occur.52For some pharmaceutical mixtures the 
excipients could lower the melting point of pure drug during compression, so the surface 
fusion could occur before reaching the melting point of drug. For some drugs like 
phenylbutazone and chloropropamide polymorphism could occur during compression and 
suggests that this mechanochemical effect is due to melting of drug during 
compression.53 
 
 
1.3.3 Evaluation of bonding mechanism 
 
 Various bonding mechanisms are involved in the consolidation of powder 
particles during compression but still it is not clear which bond is dominating in the 
formation of solid compact with strong mechanical strength. Tensile strength of the 
compact is the best parameter to assess the dominating bonding acting between the inter 
particulates. Out of three dominating bonding mechanisms, mechanical interlocking 
which is twisting or hooking together normally occurs in the particles with elongated and 
/or irregular in shape.51The above mechanism happens most of the time in compression of 
metals. The solid bridge formations are assumed to be strong bond formation due to close 
contact between particles. Whereas the attraction forces between particles are weak and 
act at a short distance. When the distance between the powder particles reduced to 100- 
1000 Å the weak long range distance forces, i.e. van der Waals forces, hydrogen bonds 
and electrostatic attraction forces are likely to occur.54  
 
 Evaluation of the dominating bonding mechanism responsible for formation of 
compact was studied by measuring electrical conductance in the compact under pressure, 
and also by using magnesium stearate as barrier against distance forces between 
particles.55,56 However, most of the pharmaceutical materials are poor conductors of 
electricity which is prerequisite for conductance. Luangtana-anan et al., described an 
alternative method to differentiate weak long range distance forces and solid bridge 
formation during compression. In this method tensile strengths of the compacts were 
evaluated after soaking the compacts in various liquids with a different dielectric 
constant. Decrease in the tensile strength results in the weak compacts with increasing 
dielectric constant of the solvent and reaches to plateau at a dielectric constant of  
between 10 and 20.49,57-59 Van der Waals forces act between most of the particles and it 
also depends on the properties of the particles and their surrounding medium. In air these 
bonds dominate in adhesion of the particles. According to Equation 1-2, the energy (W) 
between two surfaces is directly proportional to the Hamaker constant (A) and indirectly 
proportional to distance between surfaces (d). 
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ܹ = − ܣ12ߨ݀2                                            (Eq. 1-2) 
 
The interactive forces between surfaces can be expressed as Equation 1-3. 
 
                                                    
ܣݏ/݈ = 24ߨ݀2ߛݏ/݈  
                                      (Eq. 1-3) 
 
 In which γs/l, is surface energy of particles between two phases of solid and liquid 
medium. The surface energy of a particle is affected by dielectric constant. A high 
dielectric constant results in the lower surface energy and thus reduction in the strength of 
the van der Waals forces. 
 
 
1.4 Agglomeration of Micronized Powders 
 
 Even though the micronization process offers advantages among other techniques, 
it has some limitations as it generates dust, the materials possess poor flow properties 
which create formulation processing problems.60 Due to very small size, and these 
micronized powders exhibit cohesive and adhesive properties, this result in the formation 
of agglomerates. These agglomerates may break easily if they formed by weak forces but 
these may affect the disintegration and dissolution if they are strong. Formation of 
agglomerates depends on the initial particle size, generally elastic modulus and 
interparticulate bond strength. Agglomeration of particles is due to inter particulate 
bonding by weak van der Waals forces.61 Strongly agglomerated micronized drugs may 
not show any improvement in dissolution rate as the exposed external surface area of 
primary particles to the media is substantially smaller. This shows the disadvantageous 
effect of micronization. To improve the liquid penetration into the agglomerates and thus 
to increase the surface area contact use of surfactants are desirable.62-64 
 
 
1.5 Particle Agglomeration Inhibitors (PAIs) 
 
 Particle agglomeration inhibitors (PAIs) are the agents that prevent the 
aggregation of API-API particles during compression and also separate the hydrophobic 
API particles from diluents when in contact with aqueous environment by changing 
surface properties like increase in wetting and decrease in surface free energy. When 
micronized hydrophobic API powders were formed into a large solid coherent compacts 
like tablets their disintegration and dissolution will be decreased due to agglomeration 
and aggregation. By treating the hydrophobic API with particle separating agent and 
incorporating that treated particles into a tablet results in improving dissolution rate. The 
ratio of drug to particle separating agent adjusted to 1:20 to about 20:1.65The PAI’s 
should be hydrophilic in nature with low melting point and should also possess good 
compressible characteristics with high surface area. 
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1.5.1 Disintegrating agents  
 
 Particle agglomeration can be resolved by adding an excess amount of 
disintegrating agents or combination of agents such as sodium starch glycolate, 
croscarmellose sodium. As per literature more than 10 % of disintegrating agent can be 
used for poorly water soluble drug substances to get a desirable dissolution profile. 
Increase in disintegrant concentration also increases the weight of the tablet. Most 
disintegrating agents possess capillary and wicking properties for swelling and 
disintegration of tablets. Some dosage forms show differences in their disintegration and 
dissolution behavior during shelf life studies due to moisture pick-up by large quantities 
of disintegrating agents. Sometimes the disintegration process could slow down due to 
surface coating of disintegrants by micronized hydrophobic API particles or by 
magnesium stearate.66Some of the more common super disintegrating agents available in 
the market are Crospovidone (Poly Plasdone®XL-10), croscarmellose sodium (Ac-Di-
Sol®), and sodium starch glycolate (Explotab®). Among these super disintegrants 
croscarmellose sodium improved the disintegration properties from its capillary and 
swelling properties when used in dry granulation process. A very small percentage  (0.1 
to 1.0) of croscarmellose sodium was used in this thesis because of its insoluble nature in 
water. 
 
 
1.5.2 Surfactants 
 
 Surfactants are agents with hydrophilic and lipophilic groups attached together as 
head and tail respectively and these surfactants decrease the surface tension between two 
liquids or between liquid and solid surfaces. Surfactants or wetting agents can be used as 
particle agglomeration inhibitors. Block co polymers like Lutrol F 68 micronized powder 
with large surface area can be used as a PAI. The chemical structure of Lutrol F68 is 
presented in Figure 1-3. The melting point of Lutrol F 68 micro is 52-57°C. Polyethylene 
glycols are non ionic substances and can be used as a wetting agent as well as surfactants 
in preventing particle agglomeration during compression due its low melting and 
lubricating properties. They also used as lubricants and binders in tablets. The chemical 
structure of polyethylene glycol is presented in Figure 1-4.Granular PEG 3350 with high 
surface area and low melting point of 54-58°C can be used as PAI. The most important 
property of PEGs is their solubility in water.  
 
 
1.5.3 Starches 
 
 Starch is one of the naturally existing material and best disintegrating agents used 
in the most tablet formulations. Currently in the market partially gelatinized maize starch 
(Starch 1500®) is available as a binder, disintegrant, flow aid and self-lubricant. Hydroxy 
propyl starches are hydrophilic and also aid in swelling and dissolution properties of 
starches. Hydroxy propyl starches are suitable for forming highly transparent films.67 
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Figure 1-3. Lutrol F®68 
 
 
 
 
 
 
 
Figure 1-4. Polyethylene glycol 
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 Dry powder coating consists of spraying a fine powder and plasticizer on 
particles.68Currently, a hydroxyl propyl starch polymer READILYCOAT™ is using as an 
aqueous film coating material for tablets due to its excellent water solubility and 
rheological properties. 
 
 
1.6 Spray Drying 
 
 Spray drying is a process of quench cooling of solution or suspension by 
atomization through heated air in a drying chamber. Mixing with hot air the atomizer 
produces small droplets and then rapid evaporation of solvents takes place. The hot air 
can be same direction or counter-flow. Finally, the formed small fine particles are 
collected from a cyclone that separates solid particles from hot air.69 
 
 Co-processing by spray drying for excipients having superior properties compared 
to individual excipients or their physical mixtures is commonly done. This process gives 
several advantages like improvement of density, flow, porosity and compactability. 
Surface energy of materials can be modified by keeping powder bulk properties like solid 
state and compatibility by spraying drying along with surfactants.70 Spray drying of drug 
substance along with excipients is an alternative method to improve the content 
uniformity and adsorption of fine cohesive particles on coarse excipients. 
 
 
1.7 Roller Compaction 
 
 Dry granulation is one of the granulation processing methods presently most of 
the industry showing interest due to availability of directly compressible excipients. Still 
less than 20 percent of API’s are not directly compressible due their high dose, poor flow, 
poor lubrication or highly cohesive properties. 
 Even with significant disadvantages such as poor tensile strength for tablets 
produced from roller compacted granules and a relatively expensive process, formulators 
and industry often prefer the roller compaction process due to its efficient production 
output, continuous process and less labor intensive operations. The main advantages of 
the roller compaction process are: 1) increase in bulk density, 2) increase in drug 
homogeneity by decreasing segregation, 3) increase in disintegration time, and 4) 
increase in flow of granules by increasing the size of the granules. However, for high 
drug loading formulations a wet granulation process is often the only practical method.71 
 
 
1.8 Objectives 
 
 The main objective was to estimate the API particle size distribution after 
compression into tablets of a micronized API. Specific aims included- 
 
• To estimate the effect of compression force on API to API particle agglomeration 
during compression 
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• To estimate the effect of amount of API content on API to API particle 
agglomeration during compression 
• To evaluate the bonding mechanism responsible for agglomeration of API to API 
during compression  
• To prevent the API to API agglomeration during compression by various 
treatment and processing methods 
 
 Based on the Biopharmaceutical Classification System (BCS) two model drugs 
were selected. BCS class II (poorly soluble and highly permeable) drug griseofulvin and 
BCS class IV (poorly soluble and poorly permeable) drug furosemide were selected. 
 
 
1.8.1  Furosemide 
 
 Chemically furosemide is 5-(aminosulfonyl)-4-chloro-2[(2-furanylmethyl) amino] 
benzoic acid with a molecular weight of 330.7. Furosemide is light yellowish crystalline 
powder and it is practically insoluble in water with 206°C as melting point. In studies of 
dissolution rate improvement for furosemide, seven polymorphs were reported, but four 
of them were found to be true polymorphs. There were also two solvates (DMS and 
Dioxane) and one amorphous form.72-76There were no reports of polymorph dependant 
bioavailability of furosemide. Furosemide aqueous solubility at room temperature was 
reported to be as 0.01825 mg/ml at room temperature.77 Furosemide is a weak acid with 
3.8 as an acidic pKa value.78 Furosemide was the first high ceiling loop diuretic drug and 
to also be used as an antihypertensive. Furosemide USP (marketed as Lasix®) is 
available in 20, 40 and 80 mg tablets. Furosemide oral solution and its sodium salt as 
parenteral injection formulations and aerosol formulations are also available in the 
market. Oral bioavailability of furosemide was reported as approximately 60 % with an 
elimination half life of 1.5 hrs and a renal elimination of 65 % as intact drug. Furosemide 
we used in this dissertation was micronized one with mean particle size of around 5 
micron and its structure is presented in Figure 1-5. 
 
 
1.8.2  Griseofulvin 
 
 Griseofulvin is an antifungal antibiotic discovered in 1959. Chemically 
griseofulvin is (2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran-
2,1'-cyclohexan]-2'-ene-3,4'-dione and its molecular weight is 352.77 and its structure is 
presented in Figure 1-6. It is a white crystalline octahedra and rhombus shape with 
219°C as melting point. Griseofulvin was classified as a BCS class II category due to its 
poor solubility and high intestinal permeability. The aqueous solubility of griseofulvin 
was reported to be 0.03056 mg/ml and log P value of 2.18. Due to its high variability 
through oral absorption, griseofulvin is often used as a model drug for any solubility 
improvement, dissolution improvement, bioavailability improvement and novel dosage 
forms like SMEDDS/SEDDS.80 Griseofulvin is available in micro size and ultra micro 
size as tablets. GRIS® PEG 125 mg tablets are available as PEG solid dispersion dosage 
form. In humans this product showed variability when administered with and without  
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Figure 1-5. Furosemide chemical structure 
 
 
 
 
 
 
 
Figure 1-6. Griseofulvin chemical structure 
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food. Griseofulvin USP available in tablets, capsules, suspensions, powders. Oral 
absorption of griseofulvin was greater with foods containing fatty acids. Oral absorption 
of micro size griseofulvin formulations was variable (20-75 %) whereas ultramicrosize 
showed 100 % absorption when administered orally. The elimination half-life of 
griseofulvin found to be 24 hrs. By ultra micronization process the oral dose of 500 mg 
was reduced to 250 mg and proved to be bioequivalent with single 250 mg dose.81,82 
The particle size of griseofulvin we used in this disseration was around 13 micron in size. 
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CHAPTER 2.    COMPRESSION FORCE INFLUENCE ON DRUG-DRUG 
PARTICLE AGGLOMERATION DURING TABLETING OF MICRONIZED 
API 
 
 
2.1 Introduction 
 
Disintegration of tablet followed by dissolution of primary particles of it and 
absorption of dissolved drug, all these events occur in a sequence after oral 
administration.83 According to Noyes- Whitney equation the dissolution rate is directly 
proportional to surface area of dissolving drug particles, solubility of the drug in the 
solvent and indirectly proportional to thickness of the diffusion layer surrounding the 
solid particles.9 For increasing the dissolution rate of hydrophobic drugs, particle size 
reduction to micron or nano size is a common practice. This size reduction increases the 
surface area of the drug particles thereby increasing the dissolution rate. Size reduction is 
a potential advantage. However, compressing micronized drug particles i.e., bringing all 
these micronized drug particles together along with excipients to form a solid tablet could 
generate some reduction in its potential advantage. Compared to specific surface area of 
the drug particles, the effective surface area of the drug that is exposed to gastrointestinal 
fluids in a dosage form after disintegration is the most important factor to be taken into 
consideration in development of dosage form.84  
 
 However, micronization of API for increasing the surface area thereby increasing 
dissolution rate may not be adequate if the drug undergo agglomeration due to bonding 
during compression into tablets. When micronized hydrophobic drug powders are diluted 
with various tableting ingredients and compressed into tablets, the primary particle size 
of the micronized drug powder can increase significantly during compression. However, 
to evaluate this effect an intact tablet dissolution does not provide information on what is 
happening to the API particle size during compression of tablets.85  
 
 Carless et al. described as coarser particles undergo fragmentation during 
compression and fill the voids whereas finer particles during compression cannot break 
further due to their dimensions and hence fuse together. At high compression forces fine 
particles of size less than 100 microns experience high degree of shear on their surface 
and at contact points. This results in the local melting of the surfaces below its melting 
points. Upon releasing the compression force from the powder bed the aspertically 
molten surfaces solidify and forms sold bridge between particles. A larger surface area of 
micronized API particles provides a larger number of contact points and hence bonding 
between the drug particles may occur during compression. As the particle size decreases 
the tensile strength of the tablets increases; this is due to strong bonding between fine 
particles.86 Higuchi et al. described as the compression pressure increases specific surface 
area initially increases and then decreases.87 Due to variation in the distribution of 
pressure during compression inside the die the resulting compact will be 
nonhomogeneous. Also defects on the crystal surface or disorders in the lattice due to 
compaction are known to give rise to structure-sensitive diffusion of the solvent used.88-90 
Mikko et al. studied the crystal defects during compression for tolbutamide and 
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chloropropamide tablets that affects the dissolution rate by grazing incidence x-ray 
diffraction method.91 This increase can significantly alter the dissolution rate of the drug 
and reduce the absorption for certain drugs.  
 
 Khan et al. studied the effect of compaction on particle size of different type of 
materials (brittle materials, deforming materials and ductile materials with low melting 
point) and found considerably different particle size after disintegration.92 As compaction 
pressure increases the dissolution rate also increases due to fragmentation of drug 
particles within in the compact.93 However, Hirshorn et al. found a decrease in drug 
dissolution rate by increasing the compaction force and this could be due to changes in 
surface area of drug particles after compression and that it also depends on the dilution of 
drug particles with additives.94 In this chapter, the effect of drug loading and compression 
force on micronized furosemide and griseofulvin API were studied.  
 
 Tuladhar et al. described the change in the API particle size during compression 
was affected by nature of the diluents present in the formulation and also found that the 
agglomeration of fine particles during compression was independent of rate 
compression.95 Highly homogenous blend for highly cohesive micronized API can be 
achieved by blending the formulation with highly porous and freely flowing diluents. 
However, some diluents with highly indented surface may entrap the micronized drug 
and forms pockets of agglomerates which hamper the dissolution.96,97 Effect of particle 
size of diluent (lactose, di calcium phosphate dihydrate) on micronized API 
agglomeration during compression were investigated and results were discussed in this 
chapter. 
 
 Changes in the particle size of API during compression might be due to several 
mechanisms. Solid bridge formation, weak long range forces and mechanical interlocking 
are the probable mechanisms for compact formation. The strongest bond among the 
probable mechanism in bond formation, Solid bridges, described as areas in which 
particles are partially fused during compression by formation of continuous phase 
between two particles. It is very difficult to define the area responsible for agglomeration 
of particles during compression if the particles undergo weak long range forces.47,98,99 
Evaluation of mechanism responsible for agglomeration during compression can be done 
by filtering out weak long range distance forces. Luangtana-anan and Fell described the 
evaluation of bonding mechanism method by measuring the tensile strength of compacts 
after soaking in various liquids with different dielectric constants. The assumption was 
that increase in dielectric constant liquid media should decrease the tensile strength of the 
compacts if there is any weak long range distance forces are acting between the particles 
during soaking.49 
 
 The objective of the present study was to investigate the effect of compression 
force, drug loading and effect of diluent particle size on micronized API’s: Furosemide 
and griseofulvin. Particle size distribution, dissolution and characterization of particles by 
differential scanning calorimetry powder x-ray diffraction and scanning electron 
microscopy studies were performed. The dominating bond responsible for agglomeration 
of micronized griseofulvin during compression was evaluated. 
 19 
2.2 Materials and Methods 
 
 
2.2.1 Materials 
 
 Furosemide (micronized API) was purchased from Teva Pharmaceuticals, Israel. 
Micronized griseofulvin was a generous gift from Wuhan Yuancheng Technology, China. 
Modified spray dried lactose 315 (Foremost® NF Lactose) was purchased from Foremost 
Forms, Baraboo, WI. Di calcium phosphate di-hydrate (Di-Tab®) was purchased from 
Rhodia, Inc, Cranbury, NJ. Croscarmellose sodium (Ac-Di-Sol®) was obtained from 
FMC biopolymer, Philadelphia. Magnesium stearate NF was purchased from 
Mallinckrodt, St. Louis, MO. Pure n-butanol, ethanol and n-hexane were purchased from 
Sigma Aldrich, St. Louis, MO. ACS grade Acetic acid glacial was purchased from EMD 
chemicals, Billerica, MA. Sodium dodecyl sulfate and sodium acetate were purchased 
from Sigma Aldrich, St. Louis, MO. 
 
 
2.2.2 Methods 
 
 
2.2.2.1  Determination of equilibrium solubility studies 
 
 Furosemide and griseofulvin were separately added slowly in excess amount to 
stirring water and continued stirring in a shaker bath for 24 hours at 37°C temperature to 
achieve equilibrium solubility.  Samples in triplicate were withdrawn and filtered using 
25mm PVDF 0.45 µm syringe filter (Millipore Millex) and diluted with water. The 
diluted samples were assayed for furosemide and griseofulvin by UV-Visible 
spectroscopy at 272 nm and 295 nm respectively. The same procedure was also repeated 
in acetate buffer USP (pH 4.5) for furosemide. 
 
 
2.2.2.2  Preparation of saturated solutions 
 
 Saturated drug solution of furosemide and griseofulvin were prepared by adding 
excess amount of drug in distilled water with 0.1 % Tween-80 as a wetting agent and 
stirred for 12 hrs and vacuum filtered through 0.45 µm membrane filter. This saturated 
drug solution was used as a medium for disintegration of tablets and for the measurement 
of particle size by suspension method using light scattering technology. 
 
 For diluent particle size effect study a saturated furosemide solution was prepared 
in 0.1N hydrochloric acid. This saturated solution was used for disintegration of tablets 
containing DiTab as diluent to dissolve dicalcium phosphate dihydrate during 
disintegration. 
 
 
 
 20 
2.2.2.3  Preparation of blends 
 
 Furosemide and griseofulvin were accurately weighed according to formulation in 
Tables 2-1 and 2-2. Initially API’s and spray dried lactose were mixed together by 
geometric mixing by passing through #60 stainless steel mesh twice and  finally Ac-Di-
Sol was blended in a plastic bag for 5 min. 
 
 
2.2.2.4  Effect of diluent particle size 
 
 Two diluents were selected for this study. Manufactured supplied spray dried 
lactose (Foremost Lactose 315 NF) and dicalcium phosphate dihydrate (DiTab) was 
fractioned into two fractions by sifting through stainless steel mesh #60 (250 µm), #80 
(180 µm) and #200 (75 µm). Particles from both the diluents under 75 µm were collected 
and named as fraction-1 and particles under 250 µm and above 180 µm were also 
collected and named as fraction-2. Micronized furosemide was used as a model drug for 
this study. Micronized furosemide and above fractions were accurately weighed 
according to Table 2-3 and geometrically mixed by passing through #60 mesh twice and 
blended with Ac-Di-sol for 5 minutes.  
 
 
2.2.2.4.1 Estimation of diluents particle size 
 
  The mean particle sizes of above fractions were confirmed by laser diffraction 
technique using a Digisizer (Saturn Digisizer® 5200, Micromeritics). Iso propyl alcohol 
and water were used as a suspending media for measuring particle size of lactose and 
DiTab respectively. A saturated solution of lactose in isopropyl alcohol and dicalcium 
phosphate dehydrate (DiTab) in water were prepared by adding excess amounts into these 
solvents and stirred overnight and vacuum filtered.  
 
 
2.2.2.4.2 Estimation of diluents specific surface area 
 
 The specific surface area of above fractions was estimated using gas adsorption 
technique by Micromeritics Gemini 2360 surface area analyzer. The sample tubes 
containing sample were dried under stream of N2 gas at 60°C using Flowprep 060 
(Micromeritics). The specific surface area was calculated using multi point BET 
equation.  
 
 
2.2.2.5  Compression of tablets 
 
 Tablets of weight 200 mg for furosemide and 400 mg for griseofulvin were 
compressed on a hydraulic manual bench top laboratory press (Model C, Carver, Inc) 
with dual scale gauge. 5/16” FFBE (flat face bevel edge) for furosemide and 3/8” FF (flat 
face) for griseofulvin tooling were used with 7.93 mm and 9.5 mm diameter dies  
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Table 2-1. Formulations for furosemide compression force and drug loading 
study 
 
Formula F-1 F-2 F-3 
Furosemide (%)  10.00 20.00 30.00 
Spray dried lactose (%) 89.90 79.90 69.90 
Ac-Di-Sol (%) 0.10 0.10 0.10 
Total (%) 100.00 100.00 100.00 
 
 
 
 
Table 2-2. Formulations for griseofulvin compression force and drug loading 
study 
 
Formula G-1 G-2 G-3 
Griseofulvin (%)  15.00 30.00 60.00 
Spray dried lactose (%) 84.90 69.90 39.90 
Ac-Di-Sol (%) 0.10 0.10 0.10 
Total (%) 100.00 100.00 100.00 
 
 
 
 
Table 2-3. Formulation for diluent particle size effect study 
 
Formula D-1 D-2 
Furosemide (%) 30.00 30.00 
Spray dried lactose (%) 69.90 - 
DiTab (%) - 69.90 
Ac-Di-Sol (%) 0.10 0.10 
Total (%) 100.00 100.00 
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respectively. Magnesium stearate was applied to surface of both punches before 
compression and 3 sec dwell time was maintained for all the compression forces. Four 
compression forces 0.5 mT, 1.0 mT, 1.5 mT and 2.0 mT were studied. Six tablets were 
compressed for each compression force and each percent drug loading. 
 
 For diluents particle size effect study furosemide tablets of 200 mg weight from 
each diluents blend were compressed at 2mT compression force using 5/16” FFBE 
tooling. 3 sec dwell time was also maintained. 
 
 
2.2.2.6  Disintegration of tablets 
 
 Disintegration of tablets was done in QC-21™ (Hanson research) disintegration 
test system in saturated drug solution at room temperature. After disintegration of all six 
tablets process was further continued for another one more hour to dissolve all soluble 
excipients in the media. The residue was collected by vacuum filtration. The dried 
residue was assayed for API and further for particle size measurement and particle 
characterization and dissolution studies. For the diluents particle size effect study the 
tablets were also disintegrated as described above.  
 
 
2.2.2.7  Validation of disintegration process 
 
 Disintegration process was validated by measuring the API content in the residue 
at different intervals of time. Six tablets at 2mT compression force with 30% drug 
loading for each time interval were disintegrated and the residue was filtered at 0.5, 1.0 
and 2 hr using vacuum filtration unit. A known quantity of residue was dissolved in 
methanol and diluted further with methanol and absorbance was measured at λmax of 272 
nm and 294 nm for furosemide and griseofulvin respectively. 
 
 
2.2.2.8  Estimation of drug in the residue 
 
 The dried residue after filtration was analyzed for pure API’s (furosemide or 
griseofulvin) after disintegration. To ensure all soluble diluents dissolved completely 
after disintegration. A known quantity of residue was weighed in triplicate and dissolved 
in methanol and filtered through syringe filter (Acrodisc CR PTFE 0.2 µm, 25 mm) and 
diluted further with methanol. The absorbance was measured using UV/Vis 
spectrophotometer (Lambda 20, Perkin Elmer) at λmax of 272 nm and 294 nm for 
furosemide and griseofulvin respectively.  
 
 
2.2.2.9  Measurement of particle size 
 
 A Saturn Digisizer® 5200, a high resolution laser particle size analyzer, was used 
to measure the particle size of the residue from the disintegration study above. Saturated 
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furosemide/griseofulvin solution was used as dispersion media to measure the particle 
size. A suspension was prepared in saturated drug solution to measure the particle size of 
the drug residue obtained after disintegration. A homogenous liquid-solid bubble free 
suspension system was maintained by circulating the dispersed system at optimized speed 
to get a concentration with appropriate obscuration of laser light. Figure 2-1 presents the 
treatment of particles and tablets for particle size analysis and characterization. 
 
 
2.2.2.10  Modulated differential scanning calorimetry 
 
 Modulated Differential Scanning Calorimetric (MDSC) studies were carried out 
to confirm the polymorphic changes in furosemide or griseofulvin during processing and 
tablet compression using a Q2000 DSC (TA instruments).MDSC studies were performed 
with Q200 Differential Scanning Calorimeter (TA Instruments).  Samples of 
approximately 10 mg were heated in hermetic Tzero sealed aluminum pans. Melting 
temperature (Tm) was measured under N2 atmosphere at flow rate of 50 mL/min. The 
heating temperature range was from 25-220°C and ramping rate was 3°C/min and heating 
modulation was 1°C/min. The data were analyzed using Universal Analysis software. 
 
 
2.2.2.11  Scanning electron microscopy 
 
 Morphology of particles after compression was studied using an environmental 
scanning electron microscope. Powder samples of furosemide and griseofulvin were 
spread onto a double-sided adhesive carbon tape on an aluminum stub. Excess powder 
was removed by gently tapping the stub. A thin coating (~ 25 nm) of gold was applied on 
to the sample using a Hummer VII Sputtering System and observed under ESEM XL 30 
(FEI). API powder samples and samples after compression at 2 mT compression with    
30 % drug loading were observed under SEM. 
 
 
2.2.2.12  Powder X-ray diffraction 
 
 Powder X-ray diffraction studies were conducted on a X-ray Diffractomer 
(Bruker D8 Advance XRD system). The data were collected in the continuous scan mode 
using a step size of 0.04° (2θ). The scanned range was 4–40° (2θ). Furosemide and 
griseofulvin particles before and after compression at 2mT compression force and 30% 
drug loading were examined for any changes in crystallography. 
 
 
2.2.2.13  Dissolution studies 
 
 Dissolution studies were conducted for both the API’s particles before and after 
compression. A rate limiting acetate buffer at pH 4.5 medium was used for furosemide 
particles dissolution and water containing 0.54 % SDS for griseofulvin. A bathless 
dissolution system from Distek inc operated at 50 rpm paddle speed for furosemide, and  
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Figure 2-1. Scheme of particles and tablets treatment for characterization 
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75 rpm for griseofulvin at 37°C temperature. 20 mg and 15 mg powder samples of 
furosemide and griseofulvin before and after compression respectively were suspended in 
5 ml of dissolution medium and dispensed  into dissolution vessels quickly to wet the 
hydrophobic particles. On line dissolution data was collected at each 5 min intervals from 
an automated fibre optic multi channel probes with Indigo software from pION Inc. The 
absorbance data for furosemide and griseofulvin were collected at λmax of 272 nm and 
294 nm respectively. 
 
 
2.2.2.14 Drug-drug bonding mechanism 
 
 
2.2.2.14.1 Solubility studies of griseofulvin in organic solvents 
 
 Solubility studies were conducted by adding excess quantity of griseofulvin in 
hexane, n-butanol and ethanol solvents and stirred overnight. Individual samples were 
withdrawn and filtered through syringe filter (Acrodisc CR PTFE 0.2 µm, 25 mm) and 
diluted. The concentration of griseofulvin in the organic solvents was measured by 
UV/Vis spectrophotometer (Lambda 20, Perkin Elmer) at λmax of 294nm.  
 
 
2.2.2.14.2 Measurement of tensile strength of compacts 
 
 Griseofulvin API alone was compressed into compacts using a hydraulic manual 
bench top tablet press (Model C, Carver Inc) with width of 3 mm and 9.5 mm diameter 
by using 3/8” flat face tooling. Tablets of griseofulvin were compacted at four different 
forces 0.5, 1.0, 1.5 and 2.0 mT. The upper and lower punch faces were lubricated by 
applying to magnesium stearate (suspension in ethanol) for each compact. For each 
compression force five tablets were compressed and soaked for 24 hrs in a solvent media 
pre saturated with griseofulvin. The soaked compacts were dried in desiccator for another 
24 hrs before mesuring the tensile strength. For control the compacts were compressd in 
air/vacuum in the same manner and stored for 24 hrs in dessicator and measured the 
tensile strength. Solubility of drug in these solvents was also studied. Tensile strength (σ) 
of the dried tablets were derived from the crushing strength (hardness), thickness and 
diameter of the tablets according to Fell and Newton described in the Equation 2-1 
 
                                          
ߪ = 2ܨ106ߨܦܶ                                            (Eq. 2-1) 
 
Where F is force required to break the tablet diametrically, D is diameter of the tablet and 
T is thickness of the tablet. The scheme of bonding study is presented in Figure 2-2. 
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Figure 2-2. Scheme for API-API bonding study 
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2.2.2.15 Data analysis 
 
 Mean particle size data for both the API’s were used for comparison to evaluate 
the effect of compression force and effect of drug loading. Particle size data obtained 
after compression at various compression forces and drug loadings were subjected to a 
student t test and p-values were presented. 
 
 
2.3 Results and Discussion 
 
 
2.3.1  Particle size analysis and SEM characterization 
 
 In order to introduce the general process of evaluation, Figure 2-3(a) to (d) 
present the particle size distribution of furosemide and griseofulvin before compression 
and after compression at 2 mT at 30% drug loading. The particle a size of API’s used in 
the studies was confirmed by measuring particle size by laser diffraction technique. The 
particle size distribution was represented in volume frequency percent. The mean particle 
size of furosemide and griseofulvin before compression was found to be 5.04 ± 0.5 and 
13.96 ± 0.23 µm respectively. Size distribution curve for micronized furosemide showed 
a bi-modal distribution whereas for griseofulvin the particle size distribution found to be 
a unimodal distribution. Figure 2-4(a) to (d) shows the SEM images of micronized 
furosemide and griseofulvin before and after compression and disintegration. 
 
 Figure 2-3(b) and (d) shows the particle size distribution of furosemide and 
griseofulvin particles after compression. Micronized particles of furosemide formed large 
agglomerates after compression into tablet at 2 mT at 30% drug loading which results in 
shifting of its distribution to right side skew distribution in Figure 2-3(b). The 
distribution of griseofulvin after compression was similar to initial particle size 
distribution but the size of the particles was varied. SEM images of furosemide and 
griseofulvin were also correlating with their respective distributions before and after 
compression. Surface morphology of furosemide particles after compression was changed 
to big large chunks due to formation of agglomerates during compression. 
 
 Furosemide API particles before compression shown in Figure 2-4(a) were 
crystalline in structure and like polygonal, cubical and rod in shape. According to de 
Villiers et al, the micronized crystal form influences the cohesive properties and that in 
turn affects its powder properties like flow, wettability, size distribution and density.100 
SEM images of initial particles of griseofulvin in Figure 2-4(c) show crystals and 
pyramid and elongated rod like shapes. Figure 2-4(d) shows the change in crystals habit 
of griseofulvin (acicular and bipyramidal to aggregated particles) during compression at 
2mT force. Compression of hydrophobic micronized API’s along with other excipients at 
high compression force of 2mT at 30% drug loading results in the formation of strong 
agglomerates which thereby could alter the dissolution and disintegration process. 
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Figure 2-3. Particle size distribution of furosemide and griseofulvin API particles 
 
a) Furosemide particles before compression 
b) Furosemide particles after compression at 2mT with 30% drug loading 
c) Griseofulvin particles before compression 
d) Griseofulvin particles after compression at 2mT with 30% drug loading 
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Figure 2-4. SEM images of furosemide and griseofulvin API particles 
 
a) Pure furosemide particles before compression 
b) Furosemide particles after compression at 2mT with 30% drug loading 
c) Pure griseofulvin particles before compression 
d) Griseofulvin particles after compression at 2mT with 30% drug loading 
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2.3.2  Validation of disintegration process and assay of filtered residue 
 
 The filtered residue after dissolution of the soluble excipients was evaluated for 
furosemide and griseofulvin and was accepted as a viable sample if the assay was above 
95% API. This was considered as representative of the process and we further proceeded 
with that residue for characterization and particle size estimation. Validation results of 
disintegration process for furosemide and griseofulvin tablets compressed at 2mT with 
30% drug loading is presented in the Table 2-4. The assay of furosemide after 
disintegration at time intervals of 0.5, 1.0 hr were 95.67, 99.01 respectively. As the 
disintegration time increases the soluble excipients inside the tablets undergoing 
complete dissolution results in the assay of 99.06% after 2 hrs. Similarly the griseofulvin 
tablet disintegration process was validated and the assay after disintegration at time 
intervals 0.5, 1.0 and 2.0 hrs were 92.10, 95.70 and 99.73 % respectively.  
 
 
2.3.3  Effect of compression force and drug loading 
 
 Figures 2-5 and 2-6 represents the effect of compression force and drug loading 
on micronized furosemide and griseofulvin particles. An increase in the particle size was 
observed for both the API’s with increase in compression force and increase in drug 
loading. There are several mechanisms responsible for increase in particle size of large 
agglomerates of drug during compression. The micronized furosemide particles with 
mean particle size of 5.04 ± 0.5 µm were increased to 14.16 ± 3.6 µm, 42.7 ± 4.1 µm, 
39.99 ± 2.7 µm and 65.79 ± 2.8 µm with 10% drug loading at 0.5, 1.0, 1.5 and 2.0 mT 
compression forces respectively. Similarly the micronized furosemide agglomerates into 
12.29 ± 8.5 µm, 73.12 ± 7.9 µm, 84.24 ± 2.3 µm and 97.14 ± 15.3 µm with 20% drug 
loading at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively.  With increasing 
drug loading to 30% the micronized furosemide particles formed large agglomerates of 
mean particles sizes 35.85 ± 11.2 µm, 139.5 ± 6.8 µm, 144.65 ± 6.3 and 150.1 ± 17.8 µm 
at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively. No significant difference was 
observed among compression forces in agglomeration of particles at all the furosemide 
drug levels (p>0.05) whereas a significant difference was observed in particle size 
increase during compression compared for drug loadings at various compression forces 
(p<0.05). Compared to starting furosemide particle size the drug loading and 
compression force increased the particle size during compression. 
 
 The initial micronized griseofulvin particles with mean particle size of 13.96 ± 
0.23 µm agglomerated to 30.36 ± 1.06 µm, 42.89 ±1.85 µm, 49.39 ± 0.88 µm and 50.35 
± 1.15 µm with 15% drug loading at 0.5, 1.0, 1.5 and 2.0 mT compression forces 
respectively. Likewise the micronized griseofulvin particles agglomerated together 
during compression with 30% drug loading into sizes 32.41 ± 3.5 µm, 55.00 ± 7.2 µm, 
93.37 ± 6.4 µm and 111.46 ± 5.7µm at 0.5, 1.0, 1.5 and 2.0 mT compression forces 
respectively. Whereas at 60% drug loading the micronized griseofulvin formed larger 
agglomerates with mean particle sizes 51.02 ± 8.1 µm, 81.22 ± 32.89 µm, 108.9 ± 5.1 µm 
and 69.82 ± 16.96 µm at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively.  
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Table 2-4. Validation of disintegration process 
 
Time (hr)  Furosemide (%) Griseofulvin (%) 
0.5 95.67 92.10 
1.0 99.01 95.70 
2.0 99.86 99.73 
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Figure 2-5. Effect of compression force and drug loading on furosemide particles 
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Figure 2-6. Effect of compression force and drug loading on griseofulvin particles 
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 Fracturing of the formed agglomerates at 2mT compression force might be one of 
the responsible mechanisms for nonlinearity of agglomerate formation with compression 
forces. Significant difference was observed among compression forces in agglomeration 
of particles at 15% and 30% of griseofulvin drug levels (p<0.05) whereas at 60% drug 
loading  no significant difference was observed in particle size increase during 
compression compared for drug loadings at various compression forces (p>0.05). 
Compared to starting griseofulvin particle size the drug loading and compression force 
increased the particle size during compression. The increase in micronized griseofulvin 
particle size during compression may be attributed to solid bridge formation. The extent 
of particle agglomeration and the size of agglomeration during compression increases 
with increasing drug loading and compression force. The difference in the particle 
agglomeration during compression by increasing the drug content might be due to 
protection effect of lactose in lower drug content level and more interaction of drug-drug 
particle in high levels of drug content.101 And also high surface energy and greater 
surface area of micronized powders could also be a contributing factor in the formation of 
agglomerates during compression. 
 
 
2.3.4  Modulated differential scanning calorimetry 
 
 Figures 2-7 and 2-8 represents thermograms of furosemide and griseofulvin API 
particles and after compression respectively. Figure 2-7 represents the sharp endothermic 
peak at 208°C in reverse heat flow for furosemide before compression sample represents 
the crystalline nature of it. After compression at 2mT with 30% drug loading the 
furosemide did not change its solid state nature at high compression forces and showed 
nearly similar endothermic peak at 210°C. In Figure 2-8, griseofulvin particles showed 
similar endothermic peaks at 219°C before and after compression at 2mT with 30% drug 
loading. This melting endotherm corresponds to the crystalline nature of griseofulvin. 
Similarly griseofulvin did not undergo any polymorphic conversion at high compression 
forces studied at 2mT compression force.  
 
 
2.3.5  Powder X-ray diffraction studies 
 
 Figures 2-9 and 2-10 represents the difractograms of furosemide and griseofulvin 
API particles before and after compression respectively. In Figure 2-9 micronized 
furosemide before compression showed intense peaks at 5.89, 12.05, 18.01 and 24.65 
degrees. This confirms the crystalline nature of the furosemide. After compression at 
2mT for 30% drug loaded batch showed overlapping peaks for furosemide. This 
confirmed that there was no effect of compression force on polymorphic transformation 
of furosemide but some peaks at 5.89, 12.05 and 14.15 degrees were suppressed.  
 
 This suppression might be due to change in the crystal habit during the 
compression. In Figure 2-10 similar pattern of intense peaks were observed at 10.74, 
13.18, 14.78, 16.47, 23.89 and 26.71 degrees for micronized griseofulvin particles before  
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Figure 2-7. MDSC thermograms of furosemide before and after compression 
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Figure 2-8. MDSC thermograms of griseofulvin before and after compression 
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Figure 2-9. X-ray powder diffraction of furosemide particles 
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Figure 2-10. X-ray powder diffraction of griseofulvin particles 
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and after compression with very weak suppression of peak intensities were observed after 
compression. This demonstrates the speculation of no polymorphic transformation during 
compression at 2mT compression force with 30% drug loading and also maintained the 
crystallinity of both the API’s. 
 
 
2.3.6  Effect of diluent particle size 
 
 Surface area and particle size distribution of two fractions of diluents, spray dried 
lactose and DiTab® were presented in Table 2-5. Gas adsorption technique results 
showed for the small size fractions of diluents showed larger specific surface area and 
larger size fractions showed small specific surface area. Effect of these size fractions on 
agglomeration of furosemide particles at 2mT compression force with 30% drug loading 
is presented in Figure 2-11. Blend of fraction- 2 with larger particle size and smaller 
specific surface area showed increase in size of furosemide particles during compression. 
This increase in drug particle size might be due to smaller surface area available for 
deposition of micronized drug on the surface of diluents. However, the diluents blend of 
fraction-1 with smaller particle size with larger specific surface area significantly 
(p<0.05) reduced the agglomeration of drug particles during compression and this might 
be due to availability of more contact area which prevention of drug-drug particle 
binding.  
 
 
2.3.7 Dissolution studies 
 
 Generally dissolution rate also depends on the polymorphic forms of the drugs. 
High energies are needed in transition of the molecule into solution in the crystalline 
forms compared to transition of molecules in amorphous forms. Hence, the amorphous 
forms dissolve faster. However, dissolution of crystalline drugs may also change 
conversely due to imperfections generated during compression. So the energy required 
for transition into solution from these crystals may decrease and results in the increase in 
dissolution rate.102-104 Change in the dissolution rate distinctly can be observed at higher 
compression forces. The dissolution of particles after compression was studied rather 
tablets in this study to avoid any effect of compression force. Dissolution studies of 
furosemide and griseofulvin particles are presented in the Figures 2-12 and 2-13 
respectively. The dissolution study of unprocessed bulk furosemide particles was not 
successful due its hydrophobic nature hence hinders the wetting of the particles. 
 
 Furosemide particle sizes 16.16 and 81.34 µm were selected as a representative 
particle size for powder dissolution study from diluents (DiTab) size effect study. The 
agglomerates of furosemide formed during compression at 2mT with 30% drug loading 
were selected to evaluate particle size on dissolution rate instead tablets dissolution 
because the surface of these particles will be directly available to dissolution media. The 
rate of dissolution and the amount dissolved during study was slow and small for larger 
particles compared to smaller particles of furosemide. Around 56% of smaller size  
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Table 2-5. Powder properties of diluents fractions 
 
Diluent Physical property Fraction-1 Fraction-2 
Calcium phosphate di 
hydrate 
(DiTab) 
Particle size 
(µm) 
37.90 ± 0.31a 215.01 ± 0.24a 
Surface area 
(m2/gm) 1.0318 0.5889 
Spray dried lactose Particle size(µm) 92.36 ± 0.59a 233.30 ± 19.45a 
Surface area 
(m2/gm) 1.43 0.0931 
 
a-(mean ± sd, n=3) 
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Figure 2-11. Effect of particle size of diluents on furosemide during compression at 
2mT with 30% drug loading 
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Figure 2-12. Dissolution of furosemide particles 
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Figure 2-13. Dissolution of griseofulvin particles 
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particles were dissolved within 5 min whereas only 36% was dissolved for larger size 
agglomerates. Similar results were observed for griseofulvin powder particles. 
Irrespective of the presence of wetting agent in the dissolution media and processing of 
the different size powders of griseofulvin agglomerates showed difference in dissolution. 
Approximately 12% of micronized griseofulvin particles got dissolved within 5 min but it 
took 30 min to dissolve same amount of large particles of griseofulvin. This decrease in 
dissolution clearly evident that hydrophobic micronized drug particles agglomerates 
during compression which altered the dissolution rate instead of enhancing. 
 
 
2.3.8 Drug-drug bonding mechanism 
 
 For evaluating the bonding mechanism in drug-drug particle agglomeration 
micronized griseofulvin was selected due to its better compressible nature compared to 
furosemide. To avoid dissolution of griseofulvin during soaking of the compacts the 
media was pre saturated with it and its concentrations were presented in the Table 2-6. 
All the tablets were soaked in this media and tensile strength was measured after drying. 
Traditionally, based on the literature, assessment of tensile strength reveals what type of 
bonding occurs during compression.50 Moderate increase in dielectric constant not likely 
affect the solid bridge formation during compression, since solid bridges consists of 
continuous phase of solid material. The limitation of this test is solubility of the material 
at dielectric constants at greater extent which impacts the bonding structure of compacts. 
According to Figure 2-14 the tensile strength of all the tablets at increased compressed 
force were decreased initially and reached to plateau by increasing the dielectric constant 
of the liquid media. This plateau might be due to inability of dissipate agglomerated 
particles formed by solid bridge formation between the drug particles. Measurement of 
tensile strength will give a better estimate for evaluating the solid bridge formation in the 
compact. The tensile strength values at different dielectric constant media for griseofulvin 
at various compression forces were not significantly different (p>0.05) except at 1 mT 
compression force (p<0.05). The accurate measurement of solid bridge formation 
between particles in the compact can be evaluated by calculating percent remaining 
tensile strength of the compact after testing the crushing strength of the soaked and dried 
tablets. Percent remaining tensile strength of the compact can be calculated by using 
Equation 2-2. 
 
                                               
ܴܶݏ = ܶݏሺ݈ሻܶݏሺܽሻ × 100                                             (Eq. 2-2) 
 
 Where Ts (l) and Ts (a) are tensile strength of the compacts soaked in liquid and air 
respectively. Figure 2-15 represents the percent remaining tensile strength vs. dielectric 
constant. More than 60% remaining tensile strength was observed and this substantiates 
the formation of solid bridge during compression of griseofulvin alone at different 
compression force.  
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Table 2-6. Solubility of griseofulvin in organic solvents 
 
Media Dielectric constant Solubility (mg/mL) 
Air/ vacuum 1.00 NA 
Hexane 1.89 0.010 
n-Butanol 18.00 2.535 
Ethanol 24.30 4.403 
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Figure 2-14. Effect of dielectric constant and tensile strength 
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Figure 2-15.  Effect of dielectric constant on remaining tensile strength of compacts 
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 The percent remaining tensile strength of compacts was not proportional to with 
the compression force. The remaining tensile strength of griseofulvin was significantly 
higher at the plateau level which suggests the greater tendency for griseofulvin to form 
solid bridges. Eriksson et al, described the variation in the predicted and actual tensile 
strength of the compacts might be due to fracture mechanic effect or a high degree of 
deformity of particles during compression. 105 Based on these results more energy is 
required to break the formed agglomerates during compression of micronized 
griseofulvin particles. The increase in tensile strength due to fragmentation and formation 
of new surfaces can be ruled out since the starting particles itself are micron size. 
 
 
2.4 Conclusions 
 
 In conclusion, the effect of compression force study on agglomeration of 
micronized furosemide during compression showed significant increase in its particle size 
compared to initial particle size but that increase was not significant among the 
(consistent as compression force increased) compression forces. This consistent increase 
after 1 mT compression force might be large enough to exceed the elastic limit of 
furosemide particles that lead to breakage of furosemide aggregates by fracturing. 
Increasing drug loading study for furosemide showed significant increase in furosemide 
particle size during compression. 3 to 16 times increase from initial furosemide particles 
in the effect of diluent particle size study on agglomeration of furosemide particles during 
compression can be concluded that diluents with larger surface area (1.03 m2/gm or 
smaller particle size (37.90 µm) are more suitable to avoid API agglomeration during 
compression compared to diluents with larger size and smaller surface area. This might 
be due to reduced adhesion of micronized API particles on large size/smaller surface area 
diluents and higher deposition of API particles on smaller size/large surface area diluents 
which provide more interparticulate contact area. Increasing the compression force and 
drug loading study for griseofulvin particle agglomeration significantly increased the 
particle size of griseofulvin during compression except at high drug loadings. The results 
of the characterization studies SEM, thermal studies and powder x-ray diffraction for 
furosemide and griseofulvin before and after compression concluded that high 
compression forces modify the surface properties but had no effect on polymorphic 
transformation during compression. The powder dissolution results for both the API’s at 
different particles size showed effect of surface area exposed to dissolution media. The 
dominating bonding mechanism responsible for agglomerate formation was found to be 
solid bridge formation between API particles during compression. 
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CHAPTER 3.    PREVENTION OF DRUG-DRUG PARTICLE 
AGGLOMERATION DURING COMPRESSION 
 
 
3.1 Introduction 
 
 During the tablet compression the formula composition and the arrangement of 
the various particles and their nearest neighbor contacts in the die influence the bonding 
which occurs. Micronized or nano sized particles of hydrophobic drugs can agglomerate 
into larger particles due to their inter-particular bonding of various types between these 
particles during tablet compression. Agglomeration of these drug particles can be 
prevented by treating these particles with particle agglomeration inhibitors (PAI) and/or 
by using various processing techniques like roller compaction and spray drying before 
compression.  
 
 The desirable characteristics of PAI’s such as nonionic block copolymer, waxes, 
low melting polyethylene glycols and these should not interact chemically with the active 
pharmaceutical ingredients. PAI’s should possess good wetting properties, soft (low 
melting point), large surface area (small in size), hydrophilic (high HLB) in nature and 
should possess excellent compressibility. Various methods such as film coating of 
crystals, dispersion coating with soluble film former can reduce generation of hot spots 
which affects adhesion during compression.106A common process in pharmaceutical 
industry for manufacturing of tablets is powder mixing. Powder mixtures are classified 
into two major groups, free-flowing mixtures, and mixtures containing interactive 
constituents.107  
 
 Chiou et al. found a marked increase in dissolution rate for griseofulvin with PEG 
dispersions. The physical nature of these systems was not well characterized.  This 
marked increase in dissolution was due to the decreased particle size in this molecularly 
or colloidally dispersed griseofulvin in matrices of polyethylene glycol polymers.108 
 
 Gonnissen et al. described the change in the physical properties of various drugs, 
particularly surface properties by co-processing with excipients together using spray 
drying technique. This platform technology can be useful in developing ready-to-
compress powder mixtures to improve poor compactability of drugs.109,110 According to 
Makai et al. spray drying with alginates and lactose showed marked increase in the 
polarity of the surface of the particles.111 Granules containing too high concentration of 
super disintegrant can slow down the drug release from tablets due to viscous barrier 
surrounding the particles.112 
 
 Expensive and time consuming process such as co-micronization of fenofibrate a 
poor bioavailable antihyperlipoproteinemic agent improved the bioavailability 
significantly greater extent with solid surfactant (sodium luaryl sulfate) than that simply 
adding to formulation. Adsorption of surfactants on the surface of the solid is very 
important for various applications.  
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 Recently roller compaction, a dry granulation process has been commonly used 
for improving the dissolution rate of hydrophobic drugs.  Mitchell et al. describes the 
roller compaction with HPMC for poorly soluble drugs enhanced the dissolution rate due 
to its micro environmental surfactant mechanism.113 
 
 Two hydrophobic micronized furosemide and griseofulvin were selected as model 
drugs. Micronized furosemide and griseofulvin were individually compressed into tablets 
along with surface active gents having large surface area and good wetting and 
compressible properties. Today nanotechnology is increasing interest. Development of 
tablet formulation with nano sized particles is a challenging task due to aggregation of 
these particles during compression. Thus, very few tablet products with low dose are 
currently available in the market based on the nanocrystal technology. 
 
 The objective of this study was to study the effect of various surface active agents 
and various processing methods like physical mixing, roller compaction and spray drying 
in prevention of drug-drug particle agglomeration during compression. Effect of 
compression force also evaluated after treating the API with above mentioned methods 
and particle agglomeration inhibitors (PAI). Particle sizes of these drugs were measured 
before and after compression as the primary distinguishing evaluation parameter in this 
work.  
 
 
3.2 Materials and Methods 
 
 
3.2.1 Materials 
 
 Furosemide (micronized API) was purchased from Teva Pharmaceuticals, Israel. 
Micronized griseofulvin was a generous gift from Wuhan Yuancheng Technology, China. 
Modified spray dried lactose 315 (Foremost® NF Lactose) was purchased from Foremost 
Forms, Baraboo, WI. Mannitol SD 200, hydroxy propyl starch (Lycoat RS 720) were gift 
samples from Roquette America Inc, Geneva, IL. Croscarmellose sodium (Ac-Di-Sol®) 
was obtained from FMC biopolymer, Philadelphia. Poloxamer 188 (Lutrol® micro 68) 
was obtained as a gift sample from BASF Corporation, New Jersey. Polyethylene glycol 
(PEG 3350) was obtained from Dow chemicals, USA. Sodium benzoate was purchased 
from Spectrum Chemicals Manufacturing Corporation, California. Magnesium stearate 
was purchased from Mallinckrodt, New Jersey. 
 
 
3.2.2 Methods 
 
 
3.2.2.1  Effect of physical mixing  
 
 Initially API’s and PAI’s were mixed together geometrically and passed through # 
60 stainless steel mesh along with spray dried lactose monohydrate and mixed together 
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by geometric mixing by passing through #60 stainless steel mesh twice and  finally Ac-
Di-Sol was blended in a plastic bag for 5 min. All the materials were accurately weighed 
according to formulation in Tables 3-1 to 3-5. 
 
 
3.2.2.2  Effect of roller compaction 
 
 The blend of API and PAI was prepared to prevent API-API agglomeration 
during compression by roller compaction. To increases the API-PAI contact during 
processing and to avoid segregation the API was blended with PAI which has larger 
surface area and smaller in particle size than the unmodified PAI. To obtain smaller 
particles of PEG 3350 the bulk PEG 3350 was sifted through mesh # 100 and a fraction 
of particle size range less than 149µm was collected. For micronized Lutrol F68 the 
supplier provided the average particle size of 50 µm. Similarly spray dried lactose from 
bulk was selected by sieving through a stack containing mesh # 80 and mesh #200. The 
fraction that passed through mesh #80 and retained on mesh #200 was selected for this 
study. For preparation of blend for roller compaction initially the micronized 
griseofulvin/furosemide and PEG 3350/ Lutrol F68 micro were blended by passing 
through mesh # 140 (105 µm) based on drug to particle agglomeration inhibitor ratios 
mentioned in the Table 3-4 and Table 3-5. 
 
 The pre-blend was made into ribbons using TFC-Labo (Vector Corporation) mini 
roller compactor. Compaction pressure was adjusted to 5MPa and roll speed was kept at 
2 rpm and 20 rpm feed rate was adjusted to feed blend. Thick and uniform ribbons were 
produced with above parameters and the ribbons were passed through a # 40 mesh screen 
and blended with spray dried lactose and Ac-Di-Sol for15 minutes before compression. 
 
 
3.2.2.3  Effect of spray drying 
 
 A suspension of micronized furosemide was prepared by weighing 2 parts of 
Mannitol and 1 part of micronized furosemide in 100 mL of distilled water and stirred for 
4 hrs to obtain a homogeneous suspension. The suspension was spray dried using a 
BUCHI-290 (Switzerland) spray dryer with 150°C inlet and 95°C outlet temperature; the 
aspirator capacity was 100%, the feed rate was 20% and 60 ml/hr of airflow. Mannitol 
and furosemide co-processed powder was collected in cyclone separator. For comparison 
another batch of physical blend was prepared according to the formulation given in Table 
3-6 and compressed into tablets at various compression forces. The co-processed powder 
was blended with remaining excipients present in Table 3-7 and compressed into tablets. 
Preparation procedure for co-processed powder is given in Figure 3-1. Similarly a 
furosemide suspension was prepared by weighing 5 parts of micronized furosemide and 1 
part of hydroxyl propyl starch (Lycoat RS 720) in 100 ml of distilled water and stirred for 
4 hrs to get homogenous suspension. 
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Table 3-1. Formulations for effect of physical mixing on griseofulvin particles 
 
Ingredients F-1 F-2 F-3 F-4 F-5 F-6 
Griseofulvin (%) 30.00 30.00 30.00 30.00 30.00 30.00 
PEG 3350 (%) 15.00 30.00 60.00 - - - 
Lutrol F68 micro 
(%) - - - 15.00 30.00 60.00 
Spray dried lactose 
(%) 54.00 39.00 9.00 54.00 39.00 9.00 
Ac-Di-Sol (%) 1.00 1.00 1.00 1.00 1.00 1.00 
Total (%) 100.00 100.00 100.00 100.00 100.00 100.00 
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Table 3-2. Formulations for effect of physical mixing on furosemide particles 
 
Ingredients F-20 F-21 F-22 F-23 F-24 F-25 
Furosemide (%) 10.00 20.00 30.00 10.00 20.00 30.00 
Lutrol F68 micro 
(%) - - - 5.00 5.00 5.00 
Spray dried lactose 
(%) 89.90 79.90 69.90 84.90 74.90 64.90 
Ac-Di-Sol (%) 0.10 0.10 0.10 0.10 0.10 0.10 
Total (%) 100.00 100.00 100.00 100.00 100.00 100.00
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Table 3-3. Formulations for effect of physical mixing of PEG 3350 on furosemide 
particles 
 
Ingredients F-28 
Furosemide (%) 10.00 
PEG 3350 (%) 10.00 
Spray dried lactose (%) 79.90 
Ac-Di-Sol (%) 0.10 
Total (%) 100.00 
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Table 3-4. Formulations for effect of roller compaction on griseofulvin particles 
 
Ingredients F-7 F-8 F-9 F-10 F-11 F-12 
Griseofulvin (%) 30.00 30.00 30.00 30.00 30.00 30.00 
PEG 3350 (%) 15.00 30.00 60.00 - - - 
Lutrol F68 micro (%) - - - 15.00 30.00 60.00 
Spray dried lactose (%) 54.00 39.00 9.00 54.00 39.00 9.00 
Ac-Di-Sol (%) 1.00 1.00 1.00 1.00 1.00 1.00 
Total (%) 100.00 100.00 100.00 100.00 100.00 100.00
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Table 3-5. Formulations for effect of physical mixing and roller compaction on 
furosemide particles 
 
Ingredients F-26(Physical mixing) F-27 (Roller compaction)
Furosemide (%) 20.00 20.00 
Lutrol F68 micro (%) 20.00 20.00 
Spray dried lactose (%) 59.90 59.90 
Ac-Di-Sol (%) 0.10 0.10 
Total (%) 100.00 100.00 
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Table 3-6. Formulations for effect of physical mixing of mannitol on furosemide 
particles 
 
Ingredients F-13 F-14 F-15 
Furosemide (%) 10.00 20.00 30.00 
Mannitol SD 200 (%) 89.90 79.90 69.90 
Ac-Di-Sol (%) 0.10 0.10 0.10 
Total (%) 100.00 100.00 100.00 
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Table 3-7. Formulations for effect of spray drying with mannitol on furosemide 
particles 
 
Ingredients F-16 F-17 F-18 
Furosemide (%) 10.00 20.00 30.00 
Mannitol SD 200 (%) 89.90 79.90 69.90 
Ac-Di-Sol (%) 0.10 0.10 0.10 
Total (%) 100.00 100.00 100.00 
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Figure 3-1. Preparation procedure for co-processed powder of mannitol and 
furosemide 
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 Furosemide and Lycoat RS 720suspension was spray dried at 100°C inlet and 
80°C outlet temperature; aspirator capacity was 100% and feed rate of 20% and 60 ml/hr 
airflow. The co-processed powder was collected in cyclone separator and blended with 
remaining excipients presented in Table 3-8. The final blend was compressed into tablets 
at various compression forces. Procedure for preparation of co-processed powder is 
presented in Figure 3-2. 
 
 
3.2.2.4  Effect of level of super disintegrant 
 
 The effect of the level of super disintegrant was evaluated for preventing the 
agglomeration of API during compression. Micronized furosemide and spray dried 
lactose monohydrate were accurately weighed by varying the Ac-Di-Sol levels according 
to Table 3-9. Initially furosemide and spray dried lactose monohydrate were 
geometrically mixed together on paper and by passing through #60 stainless steel mesh 
twice. Finally Ac-Di-Sol was blended in a plastic bag for 5 min. the final blend was 
compressed into tablets at various compression forces. The compressed tablets were 
disintegrated in a furosemide saturated medium and particle size of furosemide after 
disintegration was estimated by light scattering technique. Saturated furosemide solution 
was used as medium for particle size measurement. Six portions of blend (200 mg each) 
were individually weighed and compressed for each level of compression force. 
 
 
3.2.2.5  Effect of hexane treatment 
 
 Based on the formulation micronized furosemide and spray dried lactose 
monohydrate were accurately weighed and dispersed in 150 ml of hexane and stirred 
using magnetic stirrer for 4 hours to make a slurry (furosemide and lactose were insoluble 
in hexane). The slurry was dried while stirring under fume hood in a crucible. The dried 
residue was further dried under vacuum oven at 60°C for 24 hours to get rid of any 
residual hexane. The residue was characterized for surface morphology by using 
Scanning Electron Microscopy. Final blend was prepared based on the formulation in 
Table 3-10. 
 
 
3.2.2.6  Compression of tablets 
 
 Tablets of weight 200 mg for furosemide and 400 mg for griseofulvin were 
compressed on a Carver hydraulic manual bench top laboratory press (Model C, Carver, 
Inc) with dual scale gauge. 5/16” FFBE (flat face bevel edge) for furosemide and 3/8” FF 
(flat face) for griseofulvin tooling were used with 7.93 mm and 9.5 mm diameter tooling 
was used respectively. Lubricant, magnesium stearate was applied externally to the faces 
of upper and lower punches before each tablet compression. 
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Table 3-8. Formulations for effect of spray drying with Lycoat RS 720 on 
furosemide particles 
 
Ingredients F-19 
Furosemide (%) 30.00 
Lycoat RS 720 (%) 1.00 
Mannitol SD 200 (%) 68.90 
Ac-Di-Sol (%) 0.10 
Total (%) 100.00 
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Figure 3-2. Preparation procedure for co-processed furosemide and Lycoat RS 
720 powder 
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Table 3-9. Formulations for level of super disintegrant 
  
Ingredients F-29 F-30 F-31 
Furosemide (%) 30.00 30.00 30.00 
Spray dried lactose (%) 69.90 69.00 68.00 
Ac-Di-Sol (%) 0.10 1.00 2.00 
Total (%) 100.00 100.00 100.00 
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Table 3-10. Formulation for hexane treatment effect for furosemide 
 
Ingredients F-32 
Furosemide (%) 30.00 
Spray dried lactose (%) 69.90 
Ac-Di-Sol (%) 0.10 
Total (%) 100.00 
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3.2.2.7  Disintegration of tablets 
 
 Disintegration of tablets was done in QC-21™ disintegration test system in 
saturated drug solution at room temperature. The disintegration was continued further for 
another one hour after disintegration of tablets to dissolve all soluble excipients in the 
media. The residue was collected by vacuum filtration unit with 0.45µm nylon filters and 
proceeds further for particle size measurement and characterization. 
 
 
3.2.2.8  Particle size analysis 
 
 A Saturn Digisizer® 5200, a high resolution laser particle size analyzer attached 
with low volume liquid sampling handling unit, was used to measure the particle size of 
the residue after the disintegration study. The low volume LSHU holds only 100 ml of 
saturated medium for carrying the sample and the circulation pump rate was adjusted to 
6L per minute. Each sample was analyzed three times. Saturated furosemide solution for 
furosemide samples and saturated griseofulvin solution for griseofulvin samples was used 
as dispersion media to measure the particle size. A small suspension sample was prepared 
in saturated drug solution to measure the particle size of the drug residue obtained after 
disintegration process. Particle size data obtained after compression at various 
compression forces and treatments were subjected to a student t test and p-values were 
presented. 
 
 
3.2.2.9  Modulated differential scanning calorimetry 
 
 Modulated Differential Scanning Calorimetric (MDSC) studies were carried out 
to confirm the polymorphic changes in furosemide and griseofulvin in the samples during 
processing and tablet compression using a Q2000 DSC (TA instruments). The data were 
analyzed using Universal Analysis software. Thermograms reverse heat flow was plotted 
against temperature. 
 
 
3.2.2.10 Scanning electron microscopy studies 
 
 Surface morphologies of particles were studied using an environmental scanning 
electron microscope (SEM). SEM evaluation was conducted by spreading samples onto 
double-sided adhesive carbon tape on an aluminum stub. A thin coating (~ 25 nm) of gold 
was applied on to the sample using a Hummer VII Sputtering System and the coated 
sample stubs were mounted and focused under ESEM XL 30 (FEI). All the samples were 
observed at an energy of 30 KV and various magnifications. 
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3.3 Results and Discussion 
 
 
3.3.1  Effect of physical mixing 
 
 Effect of physical mixing of griseofulvin and Particle Agglomeration Inhibitors 
(PEG 3350/Lutrol F68 micro) at various ratios’ on micronized griseofulvin particles 
during compression is presented in Figures 3-3 and 3-4. Both the PAI’s showed decrease 
in the particle agglomeration of griseofulvin as the ratio of GSF to PAI decreases when 
compared to without PAI. The micronized griseofulvin particles with mean particle size 
of 13.96 ± 0.23 µm were increased to 55.00 ± 7.2 µm and 111.46 ± 5.7µm without PAI at 
30% drug loading compressed at 1.0 and 2.0 mT forces respectively. After physical 
treatment with  PEG 3350 in F-1(1:0.5), F-2( 1:1) and F-3 (1:2) formulations, the 
micronized griseofulvin particles agglomerates with mean particle size of 46.59 ± 2.28 
µm,  60.64 ± 1.33 µm and 50.99 ± 2.35 µm  at 1mT compression force and 72.06 ± 2.49 
µm, 68.25 ± 1.46 µm and 60.13 ± 2.13 µm at 2mT compression force respectively with 
30% drug loading.  
 
 Similarly by physical treatment with Lutrol F68 micro a nonionic block co-
polymer in the formulations F-4 (1:0.5), F-5 (1:1) and F-6 (1:2) decreased the 
agglomeration of micronized griseofulvin particles during compression at 1mT and 2 mT 
compared to without PAI treatment. The mean particle size of griseofulvin after physical 
treatment with Lutrol F68 micro was found to be 37.05 ± 2.56 µm, 32.50 ± 3.06 µm and 
21.88 ± 0.91 µm at 1mT compression force and 52.77 ± 1.15 µm, 37.17 ± 2.51 µm and 
35.39 ± 0.99 µm at 2mT compression force respectively with 30% drug loading. 
Combination of properties like high surface area, low melting point and superior surface 
active properties of Particle agglomeration inhibitors (PEG 3350 and Lutrol F 68 micro) 
might be responsible in reducing the agglomeration of micronized griseofulvin particles 
during compression.  
 
 Shah et al. described the high energy ordered mixtures provide the more 
advantages than simple ordered mixtures in deaggregation of cohesive drugs by 
improving the efficiency of high surface area carrier and hydrophilic nature of lactose.114 
 
 Figure 3-5 represents the particle size of furosemide agglomerates formed during 
compression of formulations without PAI (F-20, F-21 and F-22) and with Lutrol F68 
micro (F-23, F-24 and F-25). In Formulations F-23 to F-25, furosemide was physically 
mixed with Lutrol F68 micro (PAI) at decreasing ratios of drug to PAI (0.5 to 0.17). 
Micronized furosemide agglomeration during compression was decreased with 
decreasing ratios of drug to PAI. Treatment with Lutrol F68 micro, the 5.04 µm sized 
furosemide was agglomerated only from to 10.82 ± 3.1 µm, 49.66 ± 1.03 µm and 89.52 ± 
3.79 µm at furosemide to Lutrol ratio 0.5, 0.25 and 0.17 after compression at 2mT 
compression force respectively. The percent reduction in the agglomeration of 
micronized furosemide during compression in the presence of Lutrol F68 micro presented 
in the Figure 3-6.  
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Figure 3-3. Effect of physical mixing with PEG 3350 on griseofulvin particles 
during compression 
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Figure 3-4. Effect of physical mixing with Lutrol F68 on griseofulvin particles 
during compression 
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Figure 3-5. Effect of physical mixing of Lutrol F68 micro on furosemide particles 
during compression 
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Figure 3-6. Effect of ratio of level of Lutrol F68 micro on agglomeration of 
furosemide particles during compression 
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 Prevention of agglomeration during compression of furosemide particles was 
achieved by physical treatment with PEG 3350 in formulation F-28 at 1:1ratio of API to 
PAI and the mean particle size of agglomerates were 8.42 µm and 21.09 µm at 1mT and 
2.0 mT respectively. 
 
 
3.3.2  Effect of roller compaction 
 
 SEM images of griseofulvin particles, after roller compaction treatment with 
Lutrol F68 micro and PEG 3350 are presented in Figure 3-7(a), (b) and (c) respectively. 
Effect of roller compaction of griseofulvin and Particle Agglomeration Inhibitors (PEG 
3350/Lutrol F68 micro) at various ratios’ on micronized griseofulvin particles during 
compression is presented in Figures 3-8 and 3-9. Both the PAI’s showed decrease in the 
particle agglomeration of griseofulvin as the ratio of GSF to PAI decreases. The 
micronized griseofulvin particles with mean particle size of 13.96 ± 0.23 µm were 
increased to 55.00 ± 7.2 µm and 111.46 ± 5.7µm with 30% drug loading at 1.0 and 2.0 
mT compression forces respectively. After roller compaction treatment with PEG 3350 in 
F-7(1:0.5), F-8( 1:1) and F-9 (1:2) This is decreasing ratio of GSF to PAI formulations 
the micronized griseofulvin particles agglomerates with mean particle size of 74.17 ± 
6.10 µm,  77.22  ± 4.98 µm and 29.68 ± 0.96 µm  at 1mT compression force and 78.19 ± 
4.23 µm, , 79.99 ± 3.34 µm and 47.00 ± 1.95 µm at 2mT compression force respectively 
with 30% drug loading. The interference of point to point contact and the low melting 
point of PEG 3350 and its surface active properties might be responsible for reduction in 
the agglomeration of micronized griseofulvin particles during compression.   
 
 Similarly by roller compaction treatment with Lutrol F68 micro a nonionic block 
co-polymer in the formulations F-10 (1:0.5), F-11 (1:1) and F-12 (1:2) decreased the 
agglomeration of micronized griseofulvin particles during compression at 1mT and 2 mT 
compared to without PAI. The mean particle size of griseofulvin after roller compaction 
treatment with Lutrol F68 micro was found to be 40.89 ± 0.92 µm, 53.93 ± 2.04 µm and 
40.03 ± 2.01 µm at 1mT compression force and 62.28 ± 1.46 µm, 49.58 ± 1.43 µm and 
32.00 ± 1.02 µm at 2mT compression force respectively with 30% drug loading.  
 
 Effect of physical treatment with very low percent (5%) of Lutrol F68 micro for 
furosemide in prevention of agglomeration during compression was found to be 
successful. Agglomeration of micronized furosemide during compression at 1mT and 
2mT forces for Formulations F-26(physical treatment) and F-27 (roller compaction 
treatment) at 1:1 ratio of API to PAI (Lutrol F68 micro) was found to be much less. The 
mean particle size of agglomerated furosemide in Figure 3-10 during compression was 
21.88 ± 5.6 µm, 29.37 ± 2.00 µm and 8.97 ± 3.02 µm and 36.23 ± 2.57 µm at 1mT and 
2mT forces respectively. This low melting point nature and more uniform spreading of 
Lutrol F68 micro during roller compaction might be responsible for preventing drug-drug 
agglomeration during compression process. 
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Figure 3-7. SEM image of (a) griseofulvin API particles (b) roller compacted 
griseofulvin + Lutrol F68 micro (c) roller compacted griseofulvin + PEG 3350 
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Figure 3-8. Effect of roller compaction with PEG 3350 on griseofulvin particles 
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Figure 3-9. Effect of roller compaction with Lutrol F68 micro on griseofulvin 
particles 
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Figure 3-10. Effect of physical mixing and roller compaction with Lutrol F68 
micro on furosemide particles during compression 
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3.3.3  Effect of spray drying 
 
 
3.3.3.1  Mannitol SD 200 
 
 Figure 3-11(a) and (b) represents the particle size distribution of furosemide 
before compression and after compression of formulation F-15 at 2 mT respectively. The 
particle size distribution was represented in volume frequency percent. The mean particle 
size of furosemide before compression was found to be 5.04 ± 0.5 µm. The size 
distribution curve for micronized furosemide showed a bi-modal distribution. Scanning 
electron microscopic images in Figure 3-12(a) represents micronized furosemide before 
compression. The effect of physical mixing with mannitol SD 200 on particle size of 
micronized furosemide during compression was evaluated by compressing the physical 
blend of furosemide at various compression forces for formulations F-13 (10% drug 
loading), F-14 (20% drug loading) and F-15 (30 % drug loading). The micron size 
furosemide particles agglomerates into large chunks during compression with mean 
particle size range of 28.3 ± 0.46, 37.02 ± 0.97, 44.68 ± 0.38, and 46.77 ± 1.83 µm at 0.5, 
1.0, 1.5 and 2.0 mT compression forces for formulation F-13 (10 % drug loading) 
respectively. For formulation F-14 with 20% drug loading these micronized furosemide 
particles agglomerates into 55.21 ± 3.1, 66.06 ± 2.51, 74.57 ± 2.76 and 83.05 ± 2.97 µm 
at 0.5, 1.0, 1.5 and 2.0 mT compression forces respectively. Similarly, for formulation F-
15 these drug particles agglomerates into 76.13 ± 3.25, 120.9 ± 7.25, 117.9 ± 16.67 and 
128.7 ± 7.51 µm. Figure 3-12(b) represents furosemide particles after compression at 2 
mT for formulation F-15(30% drug loading). Furosemide particles before compression 
were polygonal structure, cubical and rod in shape after compression these particles 
formed large agglomerates with narrow distribution shown in Figure 3-12. SEM image 
of furosemide was also correlating with the respective distributions before and after 
compression. Surface morphology of furosemide particles after compression was changed 
to rough, large chunks of agglomerates. Figure 3-13 represents effect of compression 
force and drug loading on furosemide particles with mannitol as a diluent by physical 
mixing.  
 
 Spray drying treatment of micronized furosemide with mannitol SD 200 reduced 
the agglomeration of furosemide particles during compression. SEM images in Figure 
3-14(a) to (d) represents alone Mannitol SD 200 before spray drying, furosemide + 
Mannitol SD 200 particles after spray drying, micronized furosemide API particles before 
spray drying and after compression at 2mT of spray dried blend of furosemide + 
Mannitol SD 200 formulation (F-18) respectively. The spherical shape Mannitol SD 200 
in Figure 3-14(a) did not altered its shape even after spray drying the suspension of 
furosemide in Figure 3-14(b).  Spray drying with Mannitol SD 200 successfully reduced 
the agglomeration of micronized furosemide during compression for the formulations F-
16 (10% drug loading), F-17 (20% drug loading) and F-18 (30% drug loading). The mean 
particle size of agglomerated furosemide particles after compression of formulation F-16 
was 8.44 ± 0.63 µm, 9.46 ± 0.21 µm, 10.24 ± 0.29 µm and 10.98 ± 0.55 µm at 0.5, 1.0, 
1.5 and 2.0 mT compression forces respectively. Compression of Formulation F-17 at 
0.5, 1.0, 1.5 and 2.0 mT forces agglomerates into 24.51 ± 0.78 µm, 25.86 ± 0.65 µm, 
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Figure 3-11.  Particle size distribution of furosemide particles (a) before 
compression (b) after compression at 2mT with 30% drug loading   
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Figure 3-12.  SEM image of furosemide particles (a) before compression (b) after 
compression (F-15) 
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Figure 3-13. Effect of compression force and drug loading furosemide particles 
with mannitol as a diluent by physical mixing  
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Figure 3-14. SEM image of (a) mannitol SD 200 particles (b) mannitol SD 200 + 
furosemide after spray drying (c) furosemide particles (d) furosemide particles after 
compression (F-18) 
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12.1± 0.45 µm and 20.83 ± 4.11µm respectively. SEM image of furosemide particles 
after compression at 2mT for formulation F-18 is presented Figure 3-14(d).Similarly the 
Formulation F-18 aggregates into mean particle size of 29.4 ± 5.95 µm, 33.99 ± 2.72 µm, 
23.56 ± 7.74 µm and 28.26 ± 1.16 µm at 0.5, 1.0, 1.5 and 2.0 mT respectively. Figure 
3-15 represents effect of compression force and drug loading on furosemide particles by 
spray drying process.  
 
 
3.3.3.2  Lycoat RS 720 
 
 SEM image of furosemide in Figure 3-16 shows (a) pure API particles and (b) 
Spray dried sample of furosemide with hydroxy propyl starch (Lycoat RS 720).  The 
images of spray dried mixture shows that micronized furosemide was coated by thin layer 
of hydroxy propyl starch which is specifically designed for aqueous film coating of 
immediate release solid dosage forms. Compression of blend containing coated mixture 
and remaining excipients in the formulation F-19 at 0.5, 1.0, 1.5 and 2.0 mT force results 
in the agglomerates of furosemide particle with mean particles size of 16.91 ± 0.16 µm, 
16.83 ± 0.53 µm, 15.27 ± 0.23 µm and 17.82 ± 0.62 µm respectively. Figure 3-17 
represents effect of spray drying of furosemide with Lycoat RS 720 on furosemide 
particles during compression. Based on these results aqueous film coating by spray 
drying process with hydroxyl propyl starch + micronized furosemide particles 
successfully prevented the aggregation during compression. This might be due to fast 
dispersible nature and easy film formation in aqueous environment of hydroxy propyl 
starch. 
 
 
3.3.4  Effect of concentration of super disintegrant 
 
 Incorporation of large percentage of super disintegrant in the formulation can 
prevent agglomeration of micronized drug particles during compression. However, the 
cost of the super disintegrant and formulation issues like stability, drug release needs to 
consider in adopting high percentage of super disintegrants in the formulation. The 
micronized furosemide particles in the formulations F-22, F-30 and F-31 agglomerated 
during compression with 30 % drug loading and presented in the Figure 3-18. The mean 
particle size of formed agglomerates of furosemide with low levels of super disintegrant 
(0.1%) were 139.5± 6.8 µm and 150.1 ± 17.7 µm at 1mT and 2mT compression force 
respectively. Similarly with increasing levels of super disintegrant 1.0 % and 2% of Ac-
Di-Sol in the formulations F-30 and F-31, the micronized furosemide particles 
agglomerated with the mean particle size of 61.58 ± 4.11µm, 84.64 ± 4.78 µm and 64.1 ± 
3.5 µm, 74.07 ± 4.98 µm at 1mT and 2mT compression force respectively. These results 
showing that increasing the concentration of super disintegrant in the formulation could 
not fully prevent the agglomeration of micronized furosemide particles during 
compression at 30% drug loading. However some particle agglomeration was prevented 
with increasing levels of super disintegrant. The capillary action of superdisintegrant at 
high concentration during disintegration of tablets might be responsible for this reduction 
in the particle size of agglomerates.  
 82 
 
 
 
Figure 3-15. Effect of compression force and drug loading on furosemide particles 
by spray drying process 
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Figure 3-16. SEM image (a) furosemide particles (b) furosemide + Lycoat RS 720 
spray dried particles 
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Figure 3-17. Effect of spray drying of furosemide with Lycoat RS 720 on 
furosemide particles during compression 
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Figure 3-18. Effect of AC-Di-Sol concentration on furosemide particles during 
compression 
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3.3.5  Effect of hexane treatment 
 
 Agglomeration of micronized furosemide during compression can be prevented 
by treating with Hexane. The SEM images in the Figure 3-19(a) to (c) shows furosemide 
coated spray dried lactose particles after hexane treatment at 400X, 200X and 6400X 
magnification respectively. The dried slurry of hexane shows uniform coating of 
micronized furosemide on large particles of spray dried lactose which could help in 
preventing drug-drug particle agglomeration during compression. Figure 3-20 shows the 
effect of hexane slurry treatment of furosemide particles after compression and 
disintegration. The mean particle size of agglomerates in formulation F-32 were found to 
be 56.70 ± 5.42 µm and 97.64 ± 17.36 µm with 30% drug loading at 1mT and 2mT force 
respectively. Hexane treatment helped some extent in preventing agglomeration during 
compression compared to without treatment (F-22). This might be due to uniform 
distribution of micronized furosemide particles on the large size spray dried lactose 
particles which might have created less contact area between drug particles during 
compression. 
 
 
3.3.6  Modulated differential scanning calorimetry 
 
 Thermograms in the Figure 3-21 represent comparison of furosemide particles 
before compression and after compression. Treatment effect of on polymorphic changes 
in furosemide particles during compression was compared and a change in the melting 
point of furosemide was observed in physically treated and spray dried blends. This effect 
might be due to small portion of PAI traces in the sample or amorphous conversion of 
furosemide during treatment with PAI. Similarly the Figure 3-22 represents the 
thermograms of furosemide particles after compression at 2mT using the blend 
containing co-spray dried furosemide with Lycoat RS 720. Based on the MDSC results 
spray coating of Lycoat RS 720 (which is an aqueous film former) on furosemide 
particles did not show change any polymorphism of furosemide particles during 
compression. The sharp melting point at 210.52°C in reverse heat flow in the Figures 
3-21 and 3-22 represents the crystalline nature of furosemide. Sharp endotherm at 
195.31°C represents the melting point of Lycoat RS 720 in Figure 3-22, which is absent 
in the compressed and disintegrated tablets of blend containing Lycoat RS 720 spray 
coated furosemide particles. The compression of tablets was done at 2mT force with 30% 
drug loading. These thermograms were overlapping with the furosemide thermograms 
represent no polymorphic change during compression or spray drying. The MDSC 
thermograms in Figures 3-23 and 3-24 represent the effect of physical treatment and 
roller compaction treatment with particle agglomeration inhibitors (PEG 3350, Lutrol 
F68 micro) on griseofulvin particles during compression respectively. 
 
  The sharp endothermic peaks of griseofulvin at 218.58°C before and after 
compression at 2mT with 1:0.5 ratio of drug to PAI’s shows a polymorphic change in 
griseofulvin. This melting endotherm corresponds to the crystalline nature of griseofulvin 
before and after compression but shift in the melting point might be due to impurities in 
the material or conversion to amorphous griseofulvin.  
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Figure 3-19. SEM images (a) 400X, (b) 200X, (c) 6400X magnification of 
furosemide particles coated on lactose monohydrate particle in hexane slurry 
treatment 
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Figure 3-20. Effect of treatment with hexane on furosemide particles during 
compression 
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Figure 3-21. MDSC thermograms of furosemide particles after treatment with 
mannitol spray dried 
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Figure 3-22. MDSC thermograms of furosemide after particles after treatment 
with Lycoat RS 720 
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Figure 3-23. MDSC thermograms of griseofulvin after physical treatment with 
PEG3350 and Lutrol F68 
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Figure 3-24. MDSC thermograms of griseofulvin particles after roller compaction 
with PEG 3350 and Lutrol F68 
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3.4 Conclusions 
 
 In conclusion, furosemide and griseofulvin particles agglomeration during 
compression was prevented by treatment with particle agglomeration inhibitors like PEG 
3350 and Lutrol F68 micro. Treating the furosemide particles prior to compression with 
Lutrol F68 micro by roller compaction process significantly (p<0.05) prevented more 
agglomeration when compared to physical treatment with PAI’s. Modulated differential 
scanning calorimetry studies provided the evidence of crystallinity and also effect of 
PAI’s on polymorphic transformation during treatment and compression. Hexane 
treatment for furosemide provided significant (p<0.05) prevention in agglomeration 
during compression compared to without any treatment. Increasing level of super 
disintegrant in preventing the agglomeration during compression study for furosemide 
showed significant (p<0.05) prevention when compared at 0.1% to 1% and 2% but not at 
1% to 2% (p>0.05) which shows its limitation. Spray drying with either mannitol or 
hydroxyl propyl starch for micronized furosemide significantly (p<0.05) reduced the 
agglomeration of API particles during compression. Similarly for griseofulvin physical 
treatment with Lutrol F68 micro prevented the agglomeration significantly (p<0.05) 
during compression more successfully whereas with PEG 3350 treatment the prevention 
was not significant (p>0.05) at 1mT compression force compared to without any 
treatment. Roller compaction with Lutrol F68 micro significantly (p<0.05) prevented the 
agglomeration of griseofulvin during compression compared to without any treatment 
whereas with PEG 3350 the prevention was not significant (p>0.05) at 1mTcompression 
force. This increase in particle size of griseofulvin might be due to formation of 
griseofulvin-PEG 3350 solid dispersions. Thermal studies revealed that treatment with 
PAI’s and roller compaction processing with PAI’s affect the griseofulvin crystalline 
nature. This polymorphic change might be due to formation of solid dispersion by either 
treatment with PAI’s or during the compression. 
 
 In summary, agglomeration of micronized hydrophobic drugs during compression 
can be prevented by treating with particle agglomeration inhibitors prior to compression. 
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